International Journal of Endocrinology / 2014 / Article / Tab 1 / Clinical Study
The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil Table 1 Baseline parameters (604 recruited patients). Data are presented as mean ± standard deviation when normally distributed, median
25th–75th percentiles
when skewed, and as percentages when categorical.
Parameter Age Years 55.3 ± 12.08 Anthropometrics Weight (kg) 82.9 ± 13.46 BMI (kg/m2 ) 27.4 ± 4.15 Waist circumference (cm) 99.1 ± 11.84 Metabolism Glycaemia (mg/dL) 102 [94–114] HDL cholesterol (mg/dL) 45.9 ± 11.03 Triglycerides (mg/dL) 139 ±
100–175
Cardiovascular Systolic BP (mmHg) 131.41 ± 10.48 Diastolic BP (mmHg) 82.17 ± 6.96 Pulse pressure 49.25 ± 10.4 Heart rate 75.88 ± 8.17 Hormonal FSH (IU/mL) 6.4 ± 10.3 LH (IU/mL) 4.86 ± 5.43 Total testosterone (ng/dL) 4.04 ± 1.7 Penile CDU Peak systolic velocity (cm/s2 ) 40.4 ± 13.1 Penile resistive index 0.83 ± 0.27 Prevalence of diagnostic criteria (%) CV risk class I (MACE risk < 5%) 28.6 II (MACE risk 5–10%) 30.2 III (MACE risk 10–15%) 21.5 IV (MACE risk 15–20%) 12.3 V (MACE risk 20–30%) 5.4 VI (MACE risk > 30%) 1.9 Metabolic syndrome (yes) ≥3 criteria 30.8 Blood pressure ≥130/85 or treatment 67.0 Triglycerides ≥150 mg/dL (≥1.7 mmol/L) 37.5 HDL cholesterol ≤40 mg/dL (≤1.03 mmol/L) 33.2 Fasting glucose ≥110 mg/dL (≥6.1 mmol/L) 31.7 Waist ≥102 cm 23.6 ED severity (IIEF-5 class) Mild (17–21) 22.9 Mild to moderate (12–16) 37.7 Moderate (8–11) 21.5 Severe (<8) 17.8